key: cord-0716685-392aa10n
authors: Mondal, Ritwick; Deb, Shramana; Shome, Gourav; Ganguly, Upasana; Lahiri, Durjoy; Benito-Leon, Julián
title: COVID-19 and emerging spinal cord complications: A systematic review
date: 2021-03-21
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2021.102917
sha: 8045fa7cab2799e671321124060dcd6095d40c6a
doc_id: 716685
cord_uid: 392aa10n

BACKGROUND: : Spinal cord complications associated with coronavirus infectious disease of 2019 (COVID-19) are being widely reported. The purpose of this systematic review was to summarize so far available pieces of evidence documenting novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) mediated spinal cord demyelinating diseases. METHODS: : We used the existing PRISMA consensus statement. Data were collected from PubMed, NIH Litcovid, EMBASE and Cochrane library databases, as well as Pre-print servers (medRxiv, bioRxiv, and pre-preints.org), until September 10, 2020, using pre-specified searching strategies. RESULTS: : The 21 selected articles were all case reports and included 11 (52%) men and 10 (48%) women. The mean age was of 46.7±18.0.The neurological manifestations included weakness, sensory deficit, autonomic dysfunction, and ataxia. In most cases, elevated cerebrospinal fluid protein as well as lymphocytic pleocytosis were found. SARS-CoV-2 was detected in five (24%) patients, meanwhile in 13 (62%) patients, the testing was negative. Testing was not performed in two cases and, in one, data were unavailable. Nearly half of the cases (N=9) were associated with isolated long extensive transverse myelitis (LETM), whereas a combination of both LETM and patchy involvement was found in two. Only five patients had isolated short segment involvement and two patchy involvement. Furthermore, concomitant demyelination of both brain and spine was reported in six patients. Concerning the prognosis, most of the patients improved and the mortality rate was low (N = 2, <10%). CONCLUSION: : Spinal cord demyelination should be added to the plethora of immune mediated neurologic complications associated with COVID-19.

The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has now prevailed across the world for around 6 months since WHO declared it as a pandemic on March 11, 2020 . Initially, SARS-CoV-2 was primarily considered as a respiratory pathogen. However, with time it has behaved as a virus with the potential to cause multisystem involvement. Apart from pulmonary, renal, gastrointestinal, and hematological complications, neurological manifestations have also been reported frequently [1] . It is currently known that several central and peripheral nervous system disorders may appear following SARS-CoV-2 infection [1, 2] . Neurological features may occasionally precede the typical constitutional or respiratory symptoms of the coronavirus infectious disease of 2019 [3] . Among the severe central nervous system (CNS) manifestations, stroke is one of the most frequently reported [1] [2] [3] [4] , meanwhile demyelinating disorders and seizures are now being increasingly documented as well [1] [2] [3] [4] [5] [6] . COVID-19 related peripheral nervous system (PNS) involvement has mostly been seen in the form of Guillain-Barré syndrome (GBS) and myositis [1] [2] [3] [4] 6] . Further, spinal cord complications associated with COVID-19 are being widely reported [7] .

The inter-relationship between demyelinating disorders and COVID-19 has two dimensions. On the one hand, SARS-CoV-2 infection may lead to brain and spinal cord demyelination. On the other hand, patients with known primary demyelinating disorders may experience an exacerbation of pre-existing neurological features [1] .The purpose of this systematic review was to summarize so far available pieces of evidence documenting SARS-CoV-2 mediated spinal cord complications.

This systematic review was conducted by following the Preferred Reporting for 

In this systemic review, data were collected from PubMed, NIH Litcovid, EMBASE and Cochrane library databases, until September 10, 2020, using pre-specified searching strategies. The search strategy consisted of a variation of keywords of relevant medical subject headings (MeSH) and keywords, including "SARS-CoV-2", "COVID-19", "coronavirus", "demyelinating disorders", "multiple sclerosis" and "encephalomyelitis".

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and various other human coronaviruses were also included in our search strategy to capture related articles. We also hand-searched additional COVID-19 specific articles using the reference list of the selected studies, relevant journal websites, and renowned pre-print servers (medRxiv, bioRxiv, and prepreints.org) from 2019 to the current date for literature inclusion. To decrease publication bias, we invigilated the references of all studies potentially missed in the electrical search.

Content experts also searched the grey literature of any relevant articles.

All peer-reviewed, pre-print (not-peer-reviewed) including cohort, case-control studies, and case reports, which met the pre-specified inclusion and exclusion criteria, were included in this study.

Studies meeting the following inclusion criteria were included: (i) Studies regarding and various other human coronaviruses.

We excluded studies if COVID-19 had not been confirmed and those written in languages other than English. We also excluded review papers, viewpoints, commentaries, and studies where information related to neurological manifestations or spinal demyelination was not reported.

Before the screening process, a team of two reviewers (GS and SD) participated in the calibration and screening exercises. The first reviewer (GS) subsequently screened independently the titles and abstracts of all identified citations, meanwhile the second reviewer (SD) verified those citations and screened papers by the first reviewer (GS).

Another reviewer (UG) then retrieved and screened independently the full texts of all citations deemed eligible by the reviewer (SD) and analyzed those data. The other two reviewers (RM and DL) independently verified these extracted full texts for eligibility towards analysis and designed the overall study structure. JBL resolved disagreements whenever necessary and took final decisions regarding the study. Throughout the screening and data extraction process, the reviewers used piloted forms. In addition to the relevant clinical data, the reviewers also extracted data on the following features: study characteristics (i.e., study identifier, study design, setting, and timeframe); outcomes (qualitative and/or quantitative); clinical factors (definition and measurement methods); and study limitations. The Newcastle-Ottawa scale was used to assess the selection procedure, the comparability, and the outcomes of each reviewed study.

Both qualitative and quantitative data were expressed in percentages. Unit discordance among the variables was resolved by converting the variables to a standard unit of measurement. A p value < 0.05 was considered as statistically significant, but it could not be calculated due to insufficient data. A meta-analysis was planned to analyse the association of the demographic findings, symptoms, biochemical parameters, and outcomes, but was later omitted due to lack of sufficient data.

Around 750 articles were initially identified from the databases and 253 from different pre-prints servers. Finally, 712 articles were selected after removing the duplicates. Of these selected articles, 600 were excluded after screening titles and abstracts, leaving 112 articles for full-text review for possible inclusion in this study. Of these, 60 articles were excluded based on the inclusion and exclusion criteria for the study sample and few other articles were excluded for study types (e.g., review papers, correspondence, viewpoints, or commentaries). Fifty-two articles were finally selected for this study. Of these 52, 21 articles were included in the analysis , and the remaining 31 were synthesized narratively (See, Figure 1 and table1).

The 21 selected articles were all case reports and included 11 (52%) men and 10

(48%) women. The mean age was of 46.7 ±18.0. Fever (N=11, 52%), cough (N=6, 29%), myalgia (N=6, 29%), vomiting (N=2, 10%) and nausea (N=1, 5%) were among the most frequent COVID-19 related features (See Table 2 ). The neurological manifestations included weakness (N=14, 66.7%), sensory deficit (N=14, 66.7%) autonomic dysfunction (N=8, 3.1%), and ataxia (N=1, 4.8%) (See Table 2 ).

Biochemical analysis of cerebrospinal fluid (CSF) revealed that glucose was within the normal range in most of the cases (N=12, 57.1%), whereas one case was found with elevated glucose, another one with glucose below the normal range and the value of the remaining seven cases were not mentioned (See Table 2 ). The mean range of glucose (mg/dl) in CSF was 64.5±16.4. In only three cases, both blood and CSF glucose were mentioned (blood glucose = 135 mg/dl, CSF glucose = 73 mg/dl, ratio = 0.5 [23] ; and blood glucose = 110 mg/dl, CSF glucose = 34 mg/dl, ratio = 0.30 [26] ). In the report by Otluoglu et al [19] , the CSF glucose was 5 mmol/L (90 mg/dl), while the corresponding value of blood glucose was 105 mmol/L (1890 mg/dl), which seems to be erroneous. Apart from this, CSF protein was found to be increased in most of the cases (N=12, 57.1%), whereas in six cases (N=6, 28.6%), it was below the normal range and the value was not mentioned in the remaining three cases (See Table 2 ). Median value of CSF protein (mg/dl) was 59 (IQR 36-79.1). Certain cell count parameters, such as white blood count (N=10, 47.6%) and red blood count (N=2, 10%) were found to be elevated (See Table 2 ).

In addition, lymphocytic pleocytosis (N=4, 19.0%) was also reported (See Table 2 ). SARS-CoV-2 was detected in the CSF in five (24%) patients, by means of qualitative real-time reverse-transcriptase-polymerase-chain-reaction assay (RT-PCR) in four and IgG positivity in one (See Table 2 ). SARS-CoV-2 detection was negative in 13 (62%) patients,

whereas SARS-CoV-2 testing was not performed in two cases and data was unavailable in one case (See Table 2 ). Autoimmune profiling was negative in most cases, except two cases with positive oligoclonal bands and lupus antigen, respectively (See Tables 2 and   3 ).

Neuroimaging findings were reported in all except one patient. Among the neuroimaging modalities, MRI of the spine was done in 20 patients, whereas MRI of the brain in 16. Computed tomography (CT) scan of the spine and brain were done in one and four patients, respectively. We found that nearly half of the cases (N=9, 45%) were associated with isolated long extensive transverse myelitis (LETM), whereas a combination of both LETM and patchy involvement was found in two (See Table 3 ). Only five patients had isolated short segment involvement and two patchy involvement (See Table 3 ). Furthermore, concomitant demyelination of both brain (including the brainstem) and spine was reported in six patients (Table 3) .

Treatment was mainly carried out with corticosteroids (N=18, 86%), including intravenous methylprednisolone (N=14, 67%), intravenous dexamethasone (N=2, 10%), and oral prednisolone (N=1, 5%). Intravenous immunoglobulin was administered to five (24%) patients, meanwhile plasma exchange sessions to eight (38%). Antiviral drugs, such as acyclovir, lopinavir/ritonavir, ganciclovir and favipiravir, were administered to seven patients (33.3%), being acyclovir the most common drug of choice (N=5, 24%).

Hydroxychloroquine was administered to three (14.3%) patients. Two patients also received anti-epileptic drugs. Most of the patients recovered although they were still under treatment at the time of discharge. Specifically, approximately one-third of the discharged patients were transferred to a rehabilitation center (N=6, 28.6%) for further improvement.

Only two (10%) patients died during the period of study.

During this ongoing pandemic, clinicians and researchers worldwide have observed several immunological manifestations of SARS-CoV-2, affecting different organ systems.

In tuberculosis is a known cause of LETM [34] . From a clinician's perspective, the above observations extend the differential diagnosis of LETM to include COVID-19 related spinal cord demyelination. Concerning the prognosis, most of the patients could be discharged and the mortality rate was low (<10%).

Pathogenetic mechanisms for the development of spinal cord demyelinating diseases following SARS-CoV-2 infection may be either mediated by direct neurotropism or by aberrant immune mediated injury, the latter being the most likely.

There are several pieces of evidence to support an aberrant immune mediated injury. SARS-CoV-2 infection is known to cause a cytokine storm [35] . The proinflammatory state, induced by cytokine storm, mainly sustained by IL-6, IL-1,and TNFalpha, may be the responsible for the activation of glial cells, which may also trigger the onset of demyelination [36] . In line with this, different strains of coronaviruses, such as

HCoV-OC43 and MERS-CoV, have been found to initiate several immunopathogenic responses, which further cause the progression of demyelinating events in the CNS [37] . Direct neurotropism as a pathogenic process of demyelination did not lie far behind.

The presence of HCoV RNA in the CNS of patients with demyelinating disorders, suggests a possible association between coronaviruses and demyelination [40] . In a previous study, nucleic acids of HCoV-229E have been detected in the CNS tissue in four out of eleven MS patients, which suggests neurotropism of this species of coronavirus [41] . Moreover, coronavirus-like particles have been found from autopsies of two MS patients [42] .

Using in situ hybridization technique with cloned coronavirus cDNA probes, Murray et al. [43] detected coronavirus RNA in the demyelinating plaques in in 12 of their 22 MS patients. In addition, significant amounts of coronavirus antigen and RNA were observed in active demyelinating plaques from two patients with rapidly progressive MS [43] . Further, a

15-year-old boy, who presented with acute demyelinating encephalomyelitis (ADEM), tested positive for HCoV-OC43 in CSF using RT-PCR [44] . In a series of four patients affected with neurological complications due to MERS-CoV, one of them met some criteria for diagnosis of the ADEM [45] . Interestingly, in four of the cases included in our systematic review, SARS-CoV-2 RNA could be detected in CSF.

There are some implicit limitations in the present review. Given the notable asymmetry between the total number of affected cases and reported cases of SARS-CoV- [8] (Qatar) Acute flaccid myelitis in COVID- 19 1 AlKetbi et al [9] (UAE)

Acute myelitis as a neurological as a neurological complication of COVID-19: A case report and MRI findings Acute myelitis after SARS-CoV-2 infection: a case report Zhou et al [27] (USA)

Myelin oligodendrocyte glycoprotein antibodyassociated optic neuritis and myelitis in COVID-19 1 Zoghi et al [28] (Iran) A case of possible atypical demyelinating event of the central nervous system following COVID-19 

Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic

Epub ahead of print

Update on neurological manifestations of COVID-19

COVID-19 Pandemic: A Neurological Perspective

Neurological associations of COVID-19

Seizures associated with coronavirus infections

Neurological manifestations of COVID-19: a systematic review

Spinal cord injury and COVID-19: some thoughts after the first wave

Acute Flaccid Myelitis in COVID-19

Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings

COVID-19-associated acute transverse myelitis: a rare entity

Acute transverse myelitis in COVID-19 infection

First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease

Transverse Myelitis in a Child With COVID-19

Acute transverse myelitis in a HIV-positive patient with COVID-19

Acute necrotizing myelitis and acute motor axonal neuropathy in a COVID-19 patient

Acute Demyelinating Encephalomyelitis (ADEM) in COVID-19 infection: A Case Series

Acute transverse myelitis after COVID-19 pneumonia

Acute disseminated encephalomyelitis after SARS-CoV-2 infection

Encephalomyelitis associated with Covid-19 infection: case report

A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection

COVID-19-associated acute necrotizing myelitis

Possible Acute Disseminated Encephalomyelitis Related to Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Acute transverse myelitis associated with SARS-CoV-2: A Case-Report

Transverse myelitis related to COVID-19 infection

SARS-CoV-2 can induce brain and spine demyelinating lesions

Acute myelitis after SARS-CoV-2 infection

Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19

A case of possible atypical demyelinating event of the central nervous system following COVID-19

Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence

COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid

Miller Fisher syndrome and polineuritis cranialis in COVID-19

Longitudinal extensive transverse myelitis due to tuberculosis: a report of four cases

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

COVID-19: consider cytokine storm syndromes and immunosuppression

Coronaviruses and Central Nervous System Manifestations

Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus

Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus

Neuroinvasion by human respiratory coronaviruses

Human coronavirus gene expression in the brains of multiple sclerosis patients

Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients

Detection of coronavirus RNA and antigen in multiple sclerosis brain

Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

We are sincerely thankful to Rohan Sarkhel (Department of Computer Science and 

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Flow diagram template was adopted from PRISMA.